IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Rare conditions can be daunting, terrifying and isolating. For the people and families affected by them, the search for a ...
Design Therapeutics Inc. DSGN stock surged during the premarket session on Monday. The move came after the company reported ...
Stock Surges Following Positive Clinical UpdateShares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the ...
Investor's Business Daily on MSN
This biotech leader ran up as much as 18% — and then lost it all
Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost ...
Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
For people with a progressive genetic condition called Friedreich ataxia, which affects nerves and muscles, taking medicine for a year probably has little to no effect on measures of ataxia (problems ...
Researchers have uncovered a fundamental rule that governs how genes are physically arranged inside the cell nucleus, and how ...
Spread the loveFriedreich’s ataxia, a rare genetic disorder, presents a unique and complex set of challenges for those who live with it. While much attention is given to the physical symptoms of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results